159 related articles for article (PubMed ID: 18990146)
1. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time.
Ng MK; Van As N; Thomas K; Woode-Amissah R; Horwich A; Huddart R; Khoo V; Thompson A; Dearnaley D; Parker C
BJU Int; 2009 Apr; 103(7):872-6. PubMed ID: 18990146
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
Ross AE; Loeb S; Landis P; Partin AW; Epstein JI; Kettermann A; Feng Z; Carter HB; Walsh PC
J Clin Oncol; 2010 Jun; 28(17):2810-6. PubMed ID: 20439642
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
5. Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance.
Kotb AF; Tanguay S; Luz MA; Kassouf W; Aprikian AG
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):53-7. PubMed ID: 20938463
[TBL] [Abstract][Full Text] [Related]
6. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
[TBL] [Abstract][Full Text] [Related]
7. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
[TBL] [Abstract][Full Text] [Related]
8. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
9. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
10. Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study.
Kitagawa Y; Urata S; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Namiki M
Anticancer Res; 2015 Sep; 35(9):5031-6. PubMed ID: 26254404
[TBL] [Abstract][Full Text] [Related]
11. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
[TBL] [Abstract][Full Text] [Related]
13. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Daskivich TJ; Regan MM; Oh WK
Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
[TBL] [Abstract][Full Text] [Related]
14. Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
Kumar A; Godoy G; Taneja SS
Can J Urol; 2009 Jun; 16(3):4655-9. PubMed ID: 19497172
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
16. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer.
Stephenson AJ; Aprikian AG; Souhami L; Behlouli H; Jacobson AI; Bégin LR; Tanguay S
Urology; 2002 May; 59(5):652-6. PubMed ID: 11992834
[TBL] [Abstract][Full Text] [Related]
17. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
O'Brien MF; Cronin AM; Fearn PA; Savage CJ; Smith B; Stasi J; Scardino PT; Fisher G; Cuzick J; Møller H; Oliver RT; Berney DM; Foster CS; Eastham JA; Vickers AJ; Lilja H;
Int J Cancer; 2011 May; 128(10):2373-81. PubMed ID: 20658531
[TBL] [Abstract][Full Text] [Related]
19. Is It Time to Revisit the Role of Prostate-specific Antigen Kinetics in Active Surveillance for Prostate Cancer?
Iremashvili V; Kava BR; Manoharan M; Parekh DJ; Punnen S
Urology; 2016 Sep; 95():139-44. PubMed ID: 27130265
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]